Fortunately, there are numerous existing preclinical and clinical studies on repurposing PARP1 inhibitors into non-oncological diseases, including the aforementioned acute diseases (e.g., acute respiratory distress syndrome (ARDS), stroke)75 and chronic diseases (e.g., rheumatoid arthritis and vascular diseases).75,76 All these evidences indicate the possibility of repurposing PARP1 inhibitors as a safe therapeutic agent to treat the current acute lung disease caused by SARS-CoV-2 infection. This evidence concerns the gene PARP1 and Stroke.